Candel Therapeutics, Inc.
Candel Therapeutics, Inc.（CADL）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · CADL · 截至 2026年6月8日
活动摘要
买入笔数
1
P-Purchase only
卖出笔数
18
近12个月
买卖比
0.06
Buy/Sell (by trades)
整体情绪
Candel Therapeutics, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
CADL 季度内部人买卖趋势
CADL 内幕交易卖出 · CADL 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · CADL CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
CADL 高管卖出股份 · CADL 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Feb 23, 2026 | Manning Paul B Director | Purchase | 550,458 | $3.00M⚡ | Form 4 |
| Jul 28, 2025 | Nichols William Garrett Chief Medical Officer | Option | 937 | $1K | Form 4 |
| Jul 28, 2025 | Nichols William Garrett Chief Medical Officer | Sale | 937 | $7K | Form 4 |
| Jun 30, 2025 | Nichols William Garrett Chief Medical Officer | Option | 781 | $1K | Form 4 |
| Jun 30, 2025 | Nichols William Garrett Chief Medical Officer | Sale | 781 | $4K | Form 4 |
| Jun 25, 2025 | Tyagarajan Seshu CTO | Award | 5,353 | $25K | Form 4 |
| Jun 25, 2025 | Tak Paul Peter CEO · Director | Award | 42,826 | $200K | Form 4 |
| Jun 25, 2025 | Manning Paul B Director | Award | 1,070,663 | $5.00M⚡ | Form 4 |
| Jun 25, 2025 | Martell Christopher Director | Award | 111,349 | $520K | Form 4 |
| Jun 25, 2025 | Schoch Charles CFO | Award | 5,353 | $25K | Form 4 |
| Jun 25, 2025 | Loggia Nicoletta Director | Award | 2,141 | $10K | Form 4 |
| Jun 25, 2025 | Nabel Gary J. Director | Award | 5,353 | $25K | Form 4 |
| Jun 25, 2025 | Barone Francesca Chief Scientific Officer | Award | 4,282 | $20K | Form 4 |
| Jun 25, 2025 | PAPA JOSEPH C Director | Award | 64,239 | $300K | Form 4 |
| Mar 18, 2025 | Nichols William Garrett Chief Medical Officer | Option | 13,905 | $18K | Form 4 |
| Mar 18, 2025 | Nichols William Garrett Chief Medical Officer | Option | 4,584 | $17K | Form 4 |
| Mar 18, 2025 | Nichols William Garrett Chief Medical Officer | Sale | 45,316 | $397K | Form 4 |
| Mar 18, 2025 | Barone Francesca Chief Scientific Officer | Option | 18,000 | $28K | Form 4 |
| Mar 18, 2025 | Barone Francesca Chief Scientific Officer | Sale | 32,146 | $282K | Form 4 |
| Mar 18, 2025 | Tak Paul Peter CEO · Director | Sale | 25,772 | $226K | Form 4 |
| Mar 19, 2025 | Tak Paul Peter CEO · Director | Sale | 400 | $4K | Form 4 |
| Mar 17, 2025 | Tyagarajan Seshu CTO | Sale | 31,278 | $276K | Form 4 |
| Mar 17, 2025 | Schoch Charles See Remarks | Sale | 5,000 | $44K | Form 4 |
| Jan 15, 2025 | Barone Francesca Chief Scientific Officer | Sale | 13,534 | $98K | Form 4 |
| Jan 15, 2025 | Tyagarajan Seshu CTO | Sale | 14,322 | $103K | Form 4 |
Nichols William Garrett
Chief Medical Officer
日期
Mar 18
股数
13,905
均价
$1.29
总金额
$18K
Nichols William Garrett
Chief Medical Officer
日期
Mar 18
股数
4,584
均价
$3.75
总金额
$17K
Nichols William Garrett
Chief Medical Officer
日期
Mar 18
股数
45,316
均价
$8.76
总金额
$397K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 CADL 内幕交易
CADL 内幕交易
Candel Therapeutics, Inc.（CADL）内幕交易数据来源于公司内部人（包括Nichols William Garrett (Chief Medical Officer), Manning Paul B (Director), Tyagarajan Seshu (CTO)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。CADL内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Candel Therapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
CADL 内幕交易 · 5个问题Candel Therapeutics, Inc.（CADL）的内部人包括高管和董事，如Nichols William Garrett (Chief Medical Officer), Manning Paul B (Director), Tyagarajan Seshu (CTO)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026